Sermorelin, up close: history, evidence and realistic expectations

What sermorelin is

Your hypothalamus makes growth hormone-releasing hormone (GHRH), which tells the pituitary to release growth hormone in pulses, mostly during deep sleep. Sermorelin copies the active first portion of GHRH.

Because it works upstream, sermorelin doesn't supply growth hormone directly. Your pituitary still controls how much is released, and natural feedback signals still apply. That's the main way it differs from taking growth hormone itself.

Its regulatory history

Sermorelin was sold in the U.S. as Geref. One version was approved in 1997 to treat children with growth failure due to growth hormone deficiency, and another in 1990 to test the pituitary's ability to release growth hormone. The manufacturer discontinued both in 2008.

In 2013, the FDA published its determination that Geref was not withdrawn from sale for reasons of safety or effectiveness. Today, sermorelin in the U.S. comes from compounding pharmacies. Compounded sermorelin is not FDA-approved, has not been reviewed by the FDA for safety, effectiveness or quality and is not equivalent to the former branded injection.

What it's explored for in adults

Growth hormone and IGF-1 tend to decline with age. MedlinePlus notes that IGF-1 carries out much of growth hormone's work and is a steadier measure of it. The idea behind using sermorelin in midlife is to support that axis, with hoped-for effects on sleep quality, recovery, body composition and energy.

Studies in adults do show that sermorelin can raise growth hormone and IGF-1. Whether that translates into meaningful benefits in healthy middle-aged people is much less clear, because the trials have been small and short.

The dissolving tablet question

Geref was an injection. HealifyMD offers sermorelin as an orally dissolving tablet (ODT), which avoids needles. There are no published controlled trials of a sermorelin dissolving tablet, and how much is absorbed through the mouth hasn't been established.

That doesn't mean it can't work, but it is an honest gap. A baseline and follow-up IGF-1 can give some indication of whether your body is responding.

Risks and who should avoid it

• Possible side effects include flushing, headache, nausea and dizziness, plus mouth or injection-site irritation depending on the form.
• Growth signals could, in theory, encourage existing tumors, so sermorelin is generally avoided with active cancer or a recent cancer history.
• Changes in blood sugar are possible with higher growth hormone, so people with diabetes or prediabetes need closer monitoring.
• It is not used during pregnancy or breastfeeding.
• People with untreated thyroid problems or pituitary conditions need specialist input first.

How it compares with other options

Compared with newer growth hormone-releasing peptides, sermorelin has a longer clinical record. Several other peptides in this family, such as ipamorelin and CJC-1295, have been flagged by the FDA for safety concerns in compounding.

Compared with NAD+, which is a coenzyme involved in cellular energy rather than a hormone signal, sermorelin works on a different system. Neither has strong evidence for broad anti-aging benefits. And neither replaces the biggest natural drivers of growth hormone release: deep sleep and regular exercise.

Who tends to consider it

People who ask about sermorelin are often in their late 40s to 60s, active or trying to be, and noticing lighter sleep, slower recovery after workouts or creeping changes in body composition. Many have already looked at testosterone or menopause care.

That profile is reasonable, but it's also the profile where other causes are common. Sleep apnea, alcohol, under-recovery from training, low iron and untreated menopause symptoms can all produce the same complaints. Ruling those out first gives sermorelin, if you try it, a fair test and avoids masking something treatable.

How it's prescribed at HealifyMD

A licensed clinician reviews your goals, history and medicines and may suggest baseline labs such as IGF-1 and glucose, priced separately. If sermorelin fits, the ODT is shipped from a licensed U.S. pharmacy from $199/month, with no membership fee, and the price is confirmed at your eligibility review. Your clinician sets the dose, and follow-up is used to decide whether to continue.

If your follow-up shows little change in how you feel and no meaningful shift in IGF-1, stopping is a sensible outcome rather than a failure.